Ticlopidine (trade name
Ticlid) is an antiplatelet drug in the
thienopyridine family which is an
adenosine diphosphate (ADP) receptor inhibitor. Research initially showed that it was useful for preventing strokes and coronary stent occlusions. However, because of its rare but serious side effects of
neutropenia and
thrombotic thrombocytopenic purpura it was primarily used in patients in whom aspirin was not tolerated, or in whom dual antiplatelet therapy was desirable. With the advent of newer and safer antiplatelet drugs such as
clopidogrel and
ticagrelor, its use remained limited.